Abstract

Valproic acid (VPA) is a widely used drug for epilepsy. However, precise molecular mechanisms relevant to VPA's side effects remain elusive. This study identifies a VPA-sensitive mutant strain ( vas21 ) in fission yeast with a missense mutation (T256I) in the nucleotide sugar-binding motif of the GDP-mannose transporter Vrg4 . This mutation impairs protein glycosylation, as evidenced by altered acid phosphatase mobility. We also found that Vrg4 overexpression deteriorates cell growth. Our results highlight the role of Vrg4 in glycosylation and implicate impaired glycosylation as a potential mechanism underlying VPA sensitivity. The new allele of vrg4 will be useful in glycobiology and pharmacology.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.